U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 8228 results

Status:
Investigational
Source:
INN:furofenac
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)


Furofenac (also known as SAS 650), a drug that has antiplatelet-aggregation activity and anti-inflammatory activity combined with low ulcerogenic power. It was shown that the furofenac mechanism of action involved the modulation of the platelet cyclooxygenase pathway.
Status:
Investigational
Source:
NCT04318626: Phase 2 Interventional Recruiting Post-stroke Cognitive Impairment
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


THK-5351 is a novel tau-binding quinoline derivative used as precursors of 18F-labeled radiotracer THK-5351 F-18.
Status:
Investigational
Source:
NCT00166543: Phase 2 Interventional Completed Breast Cancer
(2004)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

TAS-108 (also known as SR-16234) is a selective estrogen receptor modulator (SERM) and has been reported to have estrogen receptor (ER) α antagonistic activity and a strong affinity with a weak partial agonistic activity to ERβ receptor. It is known that ERs play a central role in the diverse actions of estrogen. TAS-108 was studied in phase II clinical trials to treat recurrent or recurrent inoperable breast cancer. In addition, TAS-108 participated in Japan in a phase II clinical trial in Endometriosis patients. The phase III studies are being planned with the drug.
Status:
Investigational
Source:
INN:leminoprazole
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

LEMINOPRAZOLE is an inhibitor of the gastric mucosal proton pump. Its development for the treatment of peptic ulcer was discontinued.
Status:
Investigational
Source:
INN:lidanserin
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Lidanserin is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist. In conscious spontaneously hypertensive rats intravenous injection of lidanserin caused dose-dependent blood pressure reductions. Lidanserin antagonises the excitatory effect of synaptically released 5-HT on central sympathoexcitatory neurons. Lidanserin is a potential antihypertensive compound which combines vasodilatatory effects due to selective alpha 1-receptor antagonistic action and platelet antiaggregatory, antivasospastic, and vasoprotective properties due to selective 5-HT2-receptor blockade.
Status:
Investigational
Source:
INN:lonaprofen
Source URL:

Class (Stereo):
CHEMICAL (UNKNOWN)

Lonaprofen is an analgesic, antipyretic and anti-inflammatory agent.
Status:
Investigational
Source:
NCT00285103: Phase 1/Phase 2 Interventional Completed Chronic Lymphocytic Leukemia
(2005)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:lorglumide
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Lorglumide (CR1409) is the first nonpeptidic, selective and potent inhibitor of the cholecystokinin-A and cholecystokinin-B receptors. Lorglumide prevented dose-dependently the emptying of the gallbladder in both experimental models; proglumide exhibited a comparable activity at much higher doses. Lorglumide was associated with significantly inhibited cell growth of human pancreatic cancer cell line Mia PaCa-2 in vitro. Lorglumide also induced G0/G1 cell cycle arrest and apoptosis. The change of invasion ability appeared to be mediated by MMP-2 expression, which was upregulated by CCK-8S and downregulated by lorglumide. Lorglumide had been in preclinical phase for the treatment of biliary dyskinesia, pancreatitis and cancer. However, this development was discontinued.
Status:
Investigational
Source:
NCT03016221: N/A Interventional Completed Healthy
(2017)
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Status:
Investigational
Source:
NCT00543413: Phase 2 Interventional Completed Hypertension
(2007)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Showing 11 - 20 of 8228 results